Frequency of CD4+CCR6+CD161+ (A) and CD4+CCR9+α4β7+ (“gut homing”) cells (B) and their correlation with viral load (C) and immune activation parameters (D, E) prior to (T0) and fol... by Matteo Basilissi (646470)

High-throughput transcriptomic analysis of adipose tissue from control and obese individuals. by Verónica García-Alonso (2636572)

Genetic analysis of Japanese primary open-angle glaucoma patients and clinical characterization of risk alleles near <i>CDKN2B-AS1</i>, <i>SIX6</i> and <i>GAS7</i> by Yukihiro Shiga (724428)

“…Among 8 SNPs in 3 loci that showed at least nominal association (<i>P</i> < 5.00E-02) in the primary cohort, a representative SNP for each loci (rs2157719 for <i>CDKN2B-AS1</i>, rs33912345 for <i>SIX6</i>, and rs9913911 for <i>GAS7</i>) were selected. …”

Route planning task trial diagram. by Paul E. Plonski (19545054)

The structure of PCNA and the docking of small molecule inhibitors. by Jessica E. Packard (16641690)

The levels of secretion of endogenous and exogenous proteins are affected by SECReTE strength. by Osnat Cohen-Zontag (6900233)

“…<p><b>(A) SECReTE enhances the ability to grow on sucrose.…”

Reduced capacity of TE and F<10 KDa to prime allogeneic responses <i>in vitro</i>. by Cristian R. Falcón (671586)

Between-subjects time pressure conditions. by Paul E. Plonski (19545054)

“…Time pressure is common during navigation, even during route planning, for example from time constraints (e.g., a deadline), waiting periods (e.g., technological problems), or imposed urgency (e.g., someone tells you to hurry up). …”

Model depicting the effects of PCNA inhibitors on HSV-1 DNA replication and repair. by Jessica E. Packard (16641690)

“…C) Proteins that are absent or significantly decreased on replicating viral DNA in the presence of PCNA-I1 are indicated with a red x or blue arrow, respectively. …”

Effects of PCNA inhibitors on viral mRNA levels. by Jessica E. Packard (16641690)

PCNA inhibitors inhibit HSV-1 infection. by Jessica E. Packard (16641690)

Effects of shRNA-mediated MRP4 transporter knock-down on demethoxycurcumin-<i>O</i>-glucuronides excretion and cellular glucuronidation in HeLa1A1 cells. by Beibei Zhang (509356)

“…<p>(A) MRP4 knock-down decreased the excreted demethoxycurcumin-<i>O</i>-glucuronides (G1); (B) MRP4 knock-down reduced the accumlated demethoxycurcumin-<i>O</i>-glucuronides (G2) in extracellular medium; (C) MRP4 knock-down inhibited the excretion rates of G1 and G2; (D) The intracellular G1 and G2 levels were evaluated when MRP4 transporter was knock-down; (E) MRP4 knock-down resulted in decrease of overall cellular glucuronidation (G1 and G2) of demethoxycurcumin; (F) Effects of gene silencing on the protein level of MRP4. …”

<i>Tagln2</i> is a direct downstream target of <i>klf6a</i>. by Lin Wen (557398)

“…(E) ChIP-PCR of the <i>tagln2</i> promoter shows that Klf6a can bind directly to the <i>tagln2</i> promoter.…”

<i>upd3</i> loss-of-function mutations suppress the synthetic lethal phenotype of <i>Gpdh1</i>^{<i>A10/B18</i>}<i>; Ldh</i>^<i>16/17</i> double mutants. by Madhulika Rai (4352803)

Practice trial #2. by Paul E. Plonski (19545054)

Viral and cellular proteins associated with replicating HSV-1 DNA change due to PCNA inhibition. by Jessica E. Packard (16641690)

Improving osteoarthritis care by digital means - Effects of a digital self-management program after 24- or 48-weeks of treatment by Leif E. Dahlberg (7405928)

The use of NSAF to compare protein abundance in replicate viral aniPOND data sets and between different infection conditions. by Jessica E. Packard (16641690)

“…Proteins that had at least 4-fold decreased association with PCNA-I1 are presented in <a href="http://www.plospathogens.org/article/info:doi/10.1371/journal.ppat.1011539#ppat.1011539.g009" target="_blank">Fig 9B</a>. …”

DataSheet_1_Consequences of intra-canopy and top LED lighting for uniformity of light distribution in a tomato crop.docx by R. Schipper (14456997)

“…Combined intra-canopy and top lighting (50/50%) had in all directions a more uniform light absorption than intra-canopy or top lighting alone. …”

Oxa33, a novel inhibitor against GlmU_Mtb binds at allosteric site of uridyltransferase domain. by Vijay Soni (816694)

“…Showing a partial closure of uridyltransferase site (decreased volume) thereby making it unavailable for its substrates for catalysis.…”